文献速递妇科产科

遗传性卵巢癌风险人群降低风险手术后激素替代治疗可及性调查

A cross-sectional survey exploring experiences in accessing hormone replacement therapy following risk-reducing surgery for individuals with hereditary ovarian cancer risk.
PubMed 文献 · Gynecol Oncol · 2026-10-22

该横断面调查在加拿大不列颠哥伦比亚省遗传性卵巢癌风险人群中开展,共收到374份回复(应答率29.1%)。在接受双侧输卵管卵巢切除术的参与者中,41%(101/245)报告使用激素替代治疗(HRT)。回归分析显示,年龄较大、有任一癌症史及未接受HRT咨询者使用HRT的可能性更低(Bonferroni校正后均p<0.0011)。

要点

  • 接受降低风险双侧输卵管卵巢切除术者中41%报告使用HRT。
  • 22%参与者报告缺乏医护人员支持,26%报告HRT与手术绝经咨询不足。
  • 年龄较大、有癌症史及未接受HRT咨询者使用HRT可能性更低。

核心结论

  • 遗传性卵巢癌风险人群在HRT获取与使用方面存在障碍,患者需要教育和资源方面的额外支持。

研究设计与样本

  • 横断面调查,通过BC Cancer遗传性癌症项目Progeny数据库识别卵巢癌易感基因致病/可能致病胚系变异个体。
  • 共1284名潜在参与者,收到374份回复,应答率29.1%。
  • 采用描述性统计、逻辑回归及归纳性定量内容分析。

主要发现

  • 接受双侧输卵管卵巢切除术的参与者中,41%(101/245)报告使用HRT。
  • 开放文本中,22%参与者报告缺乏医护人员支持,26%报告HRT与手术绝经咨询存在缺口。
  • 回归分析中,年龄较大、有任一癌症史及未接受HRT咨询者使用HRT可能性更低(Bonferroni校正后均p<0.0011)。

临床怎么用

  • 对遗传性卵巢癌风险人群在降低风险手术前后应加强HRT与手术绝经的咨询和教育。
  • 关注年龄较大、有癌症史及未接受HRT咨询者的HRT使用障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the current landscape of hormone replacement therapy (HRT) to treat surgical menopause following bilateral salpingo-oophorectomy (BSO) in individuals with hereditary ovarian cancer risk in British Columbia, Canada. We aimed to describe current use of HRT, identify factors associated with HRT use and identify potential barriers for uptake and access. METHODS: Individuals with germline pathogenic/likely pathogenic variants in an ovarian cancer susceptibility gene were identified through the BC Cancer Hereditary Cancer Program (HCP) Progeny database. A cross-sectional survey was administered to collect participant demographics, personal and family cancer history, and participant experiences with HRT. Descriptive statistics were used to characterize the sample and logistic regression used to explore associations between sociodemographic variables and reported HRT use. Open text fields were analyzed using inductive quantitative content analysis. RESULTS: In total, 374 responses were received from 1284 potential participants (29.1% response rate). Of participants who have had a BSO, 41% (101/245) report HRT use. In open-text responses, 22% of participants reported lack of support by healthcare professionals and 26% described gaps in counselling about HRT and surgical menopause. In the regression analysis, HRT use was less likely in individuals who: were of increasing age, reported a history of any cancer type and who reported receiving no counselling about HRT (all p < 0.0011 after Bonferroni correction). CONCLUSION: Barriers to HRT access and uptake exist for individuals at increased risk of ovarian cancer. Together this data indicates that patients require additional support in this area particularly as it relates to education and resources.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Thornton S, O'Loughlin M, Nuk J, et al. A cross-sectional survey exploring experiences in accessing hormone replacement therapy following risk-reducing surgery for individuals with hereditary ovarian cancer risk. Gynecol Oncol. 2026. PMID: 42913277. doi:10.1016/j.ygyno.2026.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。